Annual report

Period2022-12-01 → 2023-11-30
Filed2024-02-22
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
MetricValuePeriodScopeSource row
Revenue¥8.6bn2022-12-01 → 2023-11-30Cons.Net sales
Revenue¥8.4bn2021-12-01 → 2022-11-30Cons.Net sales
Revenue¥7.9bn2020-12-01 → 2021-11-30dCons.Net sales (5-year summary)
Revenue¥6.6bn2019-12-01 → 2020-11-30dCons.Net sales (5-year summary)
Revenue¥7.5bn2018-12-01 → 2019-11-30dCons.Net sales (5-year summary)
Operating income¥354m2022-12-01 → 2023-11-30Cons.Operating income
Operating income¥294m2021-12-01 → 2022-11-30Cons.Operating income
Ordinary income¥345m2022-12-01 → 2023-11-30Cons.Ordinary income
Ordinary income¥303m2021-12-01 → 2022-11-30Cons.Ordinary income
Ordinary income¥386m2020-12-01 → 2021-11-30dCons.Ordinary income loss (5-year summary)
Ordinary income¥83m2019-12-01 → 2020-11-30dCons.Ordinary income loss (5-year summary)
Ordinary income¥187m2018-12-01 → 2019-11-30dCons.Ordinary income loss (5-year summary)
Profit before tax¥342m2022-12-01 → 2023-11-30Cons.Income before income taxes
Profit before tax¥283m2021-12-01 → 2022-11-30Cons.Income before income taxes
Net income (owners)¥256m2022-12-01 → 2023-11-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥219m2021-12-01 → 2022-11-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥281m2020-12-01 → 2021-11-30dCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥59m2019-12-01 → 2020-11-30dCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥147m2018-12-01 → 2019-11-30dCons.Profit loss attributable to owners of parent (5-year summary)
Net income¥256m2022-12-01 → 2023-11-30Cons.Profit loss
Net income¥219m2021-12-01 → 2022-11-30Cons.Profit loss
Total assets¥8.3bnat 2023-11-30Cons.Assets
Total assets¥8.3bnat 2022-11-30Cons.Assets
Total assets¥7.9bnat 2021-11-30dCons.Total assets (5-year summary)
Total assets¥7.2bnat 2020-11-30dCons.Total assets (5-year summary)
Total assets¥7.3bnat 2019-11-30dCons.Total assets (5-year summary)
Total liabilities¥5.7bnat 2023-11-30Cons.Liabilities
Total liabilities¥5.9bnat 2022-11-30Cons.Liabilities
Net assets / equity¥2.6bnat 2023-11-30Cons.Net assets
Net assets / equity¥2.4bnat 2022-11-30Cons.Net assets
Net assets / equity¥2.3bnat 2021-11-30dCons.Net assets
Net assets / equity¥2.0bnat 2020-11-30dCons.Net assets (5-year summary)
Net assets / equity¥1.9bnat 2019-11-30dCons.Net assets (5-year summary)
Cash and deposits¥1.0bnat 2023-11-30Cons.Cash and deposits
Cash and deposits¥911mat 2022-11-30Cons.Cash and deposits
Cash & equivalents¥1.0bnat 2023-11-30Cons.Cash and cash equivalents
Cash & equivalents¥911mat 2022-11-30Cons.Cash and cash equivalents
Cash & equivalents¥1.3bnat 2021-11-30dCons.Cash and cash equivalents
Cash & equivalents¥883mat 2020-11-30dCons.Cash and cash equivalents (5-year summary)
Cash & equivalents¥397mat 2019-11-30dCons.Cash and cash equivalents (5-year summary)
Operating cash flow¥470m2022-12-01 → 2023-11-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥21m2021-12-01 → 2022-11-30Cons.Net cash provided by used in operating activities
Operating cash flow¥785m2020-12-01 → 2021-11-30dCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥654m2019-12-01 → 2020-11-30dCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥286m2018-12-01 → 2019-11-30dCons.Net cash provided by used in operating activities (5-year summary)
Investing cash flow−¥370m2022-12-01 → 2023-11-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥243m2021-12-01 → 2022-11-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥246m2020-12-01 → 2021-11-30dCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥392m2019-12-01 → 2020-11-30dCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥907m2018-12-01 → 2019-11-30dCons.Net cash provided by used in investing activities (5-year summary)
Financing cash flow¥21m2022-12-01 → 2023-11-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥162m2021-12-01 → 2022-11-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥119m2020-12-01 → 2021-11-30dCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥222m2019-12-01 → 2020-11-30dCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥349m2018-12-01 → 2019-11-30dCons.Net cash provided by used in financing activities (5-year summary)
EPS (basic)¥209.882022-12-01 → 2023-11-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥179.752021-12-01 → 2022-11-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥230.992020-12-01 → 2021-11-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥48.732019-12-01 → 2020-11-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥120.482018-12-01 → 2019-11-30dCons.Basic earnings loss per share (5-year summary)
Net assets per share¥2,167.14at 2023-11-30Cons.Net assets per share (5-year summary)
Net assets per share¥1,980.62at 2022-11-30Cons.Net assets per share (5-year summary)
Net assets per share¥1,850.07at 2021-11-30dCons.Net assets per share (5-year summary)
Net assets per share¥1,619.73at 2020-11-30dCons.Net assets per share (5-year summary)
Net assets per share¥1,600.24at 2019-11-30dCons.Net assets per share (5-year summary)
Equity ratio31.6%at 2023-11-30Cons.Equity to asset ratio (5-year summary)
Equity ratio29.0%at 2022-11-30Cons.Equity to asset ratio (5-year summary)
Equity ratio28.5%at 2021-11-30dCons.Equity to asset ratio (5-year summary)
Equity ratio27.4%at 2020-11-30dCons.Equity to asset ratio (5-year summary)
Equity ratio26.7%at 2019-11-30dCons.Equity to asset ratio (5-year summary)
ROE10.1%2022-12-01 → 2023-11-30Cons.Rate of return on equity (5-year summary)
ROE9.4%2021-12-01 → 2022-11-30Cons.Rate of return on equity (5-year summary)
ROE13.3%2020-12-01 → 2021-11-30dCons.Rate of return on equity (5-year summary)
ROE3.0%2019-12-01 → 2020-11-30dCons.Rate of return on equity (5-year summary)
ROE7.7%2018-12-01 → 2019-11-30dCons.Rate of return on equity (5-year summary)
Employees166at 2023-11-30Cons.Number of employees
Employees171at 2022-11-30Cons.Number of employees
Employees165at 2021-11-30dCons.Number of employees
Employees173at 2020-11-30dCons.Number of employees
Employees164at 2019-11-30dCons.Number of employees
Revenue¥8.4bn2022-12-01 → 2023-11-30StandaloneNet sales
Revenue¥8.2bn2021-12-01 → 2022-11-30StandaloneNet sales
Revenue¥7.7bn2020-12-01 → 2021-11-30dStandaloneNet sales (5-year summary)
Revenue¥6.5bn2019-12-01 → 2020-11-30dStandaloneNet sales (5-year summary)
Revenue¥7.4bn2018-12-01 → 2019-11-30dStandaloneNet sales (5-year summary)
Operating income¥341m2022-12-01 → 2023-11-30StandaloneOperating income
Operating income¥249m2021-12-01 → 2022-11-30StandaloneOperating income
Ordinary income¥333m2022-12-01 → 2023-11-30StandaloneOrdinary income
Ordinary income¥262m2021-12-01 → 2022-11-30StandaloneOrdinary income
Ordinary income¥329m2020-12-01 → 2021-11-30dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥59m2019-12-01 → 2020-11-30dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥162m2018-12-01 → 2019-11-30dStandaloneOrdinary income loss (5-year summary)
Profit before tax¥330m2022-12-01 → 2023-11-30StandaloneIncome before income taxes
Profit before tax¥243m2021-12-01 → 2022-11-30StandaloneIncome before income taxes
Net income¥246m2022-12-01 → 2023-11-30StandaloneProfit loss
Net income¥185m2021-12-01 → 2022-11-30StandaloneProfit loss
Net income¥242m2020-12-01 → 2021-11-30dStandaloneNet income loss (5-year summary)
Net income¥40m2019-12-01 → 2020-11-30dStandaloneNet income loss (5-year summary)
Net income¥128m2018-12-01 → 2019-11-30dStandaloneNet income loss (5-year summary)
Total assets¥8.1bnat 2023-11-30StandaloneAssets
Total assets¥8.2bnat 2022-11-30StandaloneAssets
Total assets¥7.8bnat 2021-11-30dStandaloneTotal assets (5-year summary)
Total assets¥7.1bnat 2020-11-30dStandaloneTotal assets (5-year summary)
Total assets¥7.2bnat 2019-11-30dStandaloneTotal assets (5-year summary)
Total liabilities¥5.7bnat 2023-11-30StandaloneLiabilities
Total liabilities¥5.9bnat 2022-11-30StandaloneLiabilities
Net assets / equity¥2.5bnat 2023-11-30StandaloneNet assets
Net assets / equity¥2.2bnat 2022-11-30StandaloneNet assets
Net assets / equity¥2.1bnat 2021-11-30dStandaloneNet assets
Net assets / equity¥1.9bnat 2020-11-30dStandaloneNet assets (5-year summary)
Net assets / equity¥1.9bnat 2019-11-30dStandaloneNet assets (5-year summary)
Cash and deposits¥834mat 2023-11-30StandaloneCash and deposits
Cash and deposits¥683mat 2022-11-30StandaloneCash and deposits
EPS (basic)¥201.872022-12-01 → 2023-11-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥151.852021-12-01 → 2022-11-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥198.642020-12-01 → 2021-11-30dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥32.472019-12-01 → 2020-11-30dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥104.92018-12-01 → 2019-11-30dStandaloneBasic earnings loss per share (5-year summary)
Dividend per share¥502022-12-01 → 2023-11-30StandaloneDividend paid per share (5-year summary)
Dividend per share¥502021-12-01 → 2022-11-30StandaloneDividend paid per share (5-year summary)
Dividend per share¥502020-12-01 → 2021-11-30dStandaloneDividend paid per share (5-year summary)
Dividend per share¥302019-12-01 → 2020-11-30dStandaloneDividend paid per share (5-year summary)
Dividend per share¥302018-12-01 → 2019-11-30dStandaloneDividend paid per share (5-year summary)
Net assets per share¥2,015.67at 2023-11-30StandaloneNet assets per share (5-year summary)
Net assets per share¥1,847.66at 2022-11-30StandaloneNet assets per share (5-year summary)
Net assets per share¥1,758.24at 2021-11-30dStandaloneNet assets per share (5-year summary)
Net assets per share¥1,573.45at 2020-11-30dStandaloneNet assets per share (5-year summary)
Net assets per share¥1,571.92at 2019-11-30dStandaloneNet assets per share (5-year summary)
Equity ratio30.2%at 2023-11-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio27.6%at 2022-11-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio27.6%at 2021-11-30dStandaloneEquity to asset ratio (5-year summary)
Equity ratio26.9%at 2020-11-30dStandaloneEquity to asset ratio (5-year summary)
Equity ratio26.4%at 2019-11-30dStandaloneEquity to asset ratio (5-year summary)
ROE10.5%2022-12-01 → 2023-11-30StandaloneRate of return on equity (5-year summary)
ROE8.4%2021-12-01 → 2022-11-30StandaloneRate of return on equity (5-year summary)
ROE11.9%2020-12-01 → 2021-11-30dStandaloneRate of return on equity (5-year summary)
ROE2.1%2019-12-01 → 2020-11-30dStandaloneRate of return on equity (5-year summary)
ROE6.8%2018-12-01 → 2019-11-30dStandaloneRate of return on equity (5-year summary)
Shares issued1,220,000at 2023-11-30StandaloneTotal number of issued shares (5-year summary)
Shares issued1,220,000at 2022-11-30StandaloneTotal number of issued shares (5-year summary)
Shares issued1,220,000at 2021-11-30dStandaloneTotal number of issued shares (5-year summary)
Shares issued1,220,000at 2020-11-30dStandaloneTotal number of issued shares (5-year summary)
Shares issued1,220,000at 2019-11-30dStandaloneTotal number of issued shares (5-year summary)
Employees160at 2023-11-30StandaloneNumber of employees
Employees166at 2022-11-30StandaloneNumber of employees
Employees159at 2021-11-30dStandaloneNumber of employees
Employees167at 2020-11-30dStandaloneNumber of employees
Employees159at 2019-11-30dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Pharmaceutical Productsreportable segmentcapex2022-12-01 → 2023-11-30¥314m
Pharmaceutical Productsreportable segmentdepreciation2022-12-01 → 2023-11-30¥406m
Pharmaceutical Productsreportable segmentemployeesat 2023-11-30165 pure
Pharmaceutical Productsreportable segmentrevenue2022-12-01 → 2023-11-30¥8.6bn
Pharmaceutical Productsreportable segmentrevenue external2022-12-01 → 2023-11-30¥8.6bn
Pharmaceutical Productsreportable segmentsegment assetsat 2023-11-30¥8.3bn
Pharmaceutical Productsreportable segmentsegment profit2022-12-01 → 2023-11-30¥323m
Real Estate Leasingreportable segmentemployeesat 2023-11-301 pure
Real Estate Leasingreportable segmentrevenue2022-12-01 → 2023-11-30¥38m
Real Estate Leasingreportable segmentrevenue external2022-12-01 → 2023-11-30¥38m
Real Estate Leasingreportable segmentsegment assetsat 2023-11-30¥71m
Real Estate Leasingreportable segmentsegment profit2022-12-01 → 2023-11-30¥31m
Total Of Reportable Segments And Otherssegment totalcapex2022-12-01 → 2023-11-30¥314m
Total Of Reportable Segments And Otherssegment totaldepreciation2022-12-01 → 2023-11-30¥406m
Total Of Reportable Segments And Otherssegment totalrevenue2022-12-01 → 2023-11-30¥8.6bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-12-01 → 2023-11-30¥8.6bn
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2023-11-30¥8.3bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-12-01 → 2023-11-30¥354m
Pharmaceutical Productsreportable segmentcapex2021-12-01 → 2022-11-30¥382m
Pharmaceutical Productsreportable segmentdepreciation2021-12-01 → 2022-11-30¥396m
Pharmaceutical Productsreportable segmentrevenue2021-12-01 → 2022-11-30¥8.3bn
Pharmaceutical Productsreportable segmentrevenue external2021-12-01 → 2022-11-30¥8.3bn
Pharmaceutical Productsreportable segmentsegment assetsat 2022-11-30¥8.3bn
Pharmaceutical Productsreportable segmentsegment profit2021-12-01 → 2022-11-30¥263m
Real Estate Leasingreportable segmentrevenue2021-12-01 → 2022-11-30¥38m
Real Estate Leasingreportable segmentrevenue external2021-12-01 → 2022-11-30¥38m
Real Estate Leasingreportable segmentsegment assetsat 2022-11-30¥71m
Real Estate Leasingreportable segmentsegment profit2021-12-01 → 2022-11-30¥30m
Total Of Reportable Segments And Otherssegment totalcapex2021-12-01 → 2022-11-30¥382m
Total Of Reportable Segments And Otherssegment totaldepreciation2021-12-01 → 2022-11-30¥396m
Total Of Reportable Segments And Otherssegment totalrevenue2021-12-01 → 2022-11-30¥8.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-12-01 → 2022-11-30¥8.4bn
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2022-11-30¥8.3bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-12-01 → 2022-11-30¥294m
Pharmaceutical Productsreportable segmentemployeesat 2023-11-30159 pure
Real Estate Leasingreportable segmentemployeesat 2023-11-301 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,441
ItemContextValueUnit
Net assetsCurrentYearInstant_NonConsolidatedMember2454019000JPY
Shipping expenses and storage fee selling expensesPrior1YearDuration_NonConsolidatedMember177907000JPY
Shipping expenses and storage fee selling expensesCurrentYearDuration_NonConsolidatedMember174513000JPY
Provision of allowance for doubtful accounts sgaPrior1YearDuration_NonConsolidatedMember557000JPY
Provision of allowance for doubtful accounts sgaCurrentYearDuration_NonConsolidatedMember238000JPY
Directors compensations sgaPrior1YearDuration_NonConsolidatedMember88621000JPY
Directors compensations sgaCurrentYearDuration_NonConsolidatedMember73873000JPY
Employee payrolls and allowances general and administrative expensesPrior1YearDuration_NonConsolidatedMember336838000JPY
Employee payrolls and allowances general and administrative expensesCurrentYearDuration_NonConsolidatedMember328351000JPY
Legal welfare expenses sgaPrior1YearDuration_NonConsolidatedMember27332000JPY
Legal welfare expenses sgaCurrentYearDuration_NonConsolidatedMember26723000JPY
Research and development expenses sgaPrior1YearDuration_NonConsolidatedMember244961000JPY
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember240396000JPY
Depreciation research and development expensesPrior1YearDuration_NonConsolidatedMember64629000JPY
Depreciation research and development expensesCurrentYearDuration_NonConsolidatedMember65898000JPY
Retirement benefit expenses sgaPrior1YearDuration_NonConsolidatedMember59686000JPY
Retirement benefit expenses sgaCurrentYearDuration_NonConsolidatedMember31791000JPY
Provision for directors bonuses sgaPrior1YearDuration_NonConsolidatedMember16500000JPY
Provision for directors bonuses sgaCurrentYearDuration_NonConsolidatedMember16200000JPY
Provision for directors retirement benefits sgaPrior1YearDuration_NonConsolidatedMember14200000JPY
Provision for directors retirement benefits sgaCurrentYearDuration_NonConsolidatedMember8985000JPY
Depreciation sgaPrior1YearDuration_NonConsolidatedMember12625000JPY
Depreciation sgaCurrentYearDuration_NonConsolidatedMember15051000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)有価証券報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条第1項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2024-02-22
Fiscal year cover pageFilingDateInstant
Original text (Japanese)第122期(自 2022年12月1日 至 2023年11月30日)
Company name cover pageFilingDateInstant
Original text (Japanese)川口化学工業株式会社
Company name in english cover pageFilingDateInstantKawaguchi Chemical Industry Co., Ltd
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長  山 田 秀 行
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都千代田区内神田2丁目8番4号(同所は登記上の本店所在地であり、実際の業務は、下記で行なっております。)
Telephone number address of registered headquarter cover pageFilingDateInstant-
Name of contact person address of registered headquarter cover pageFilingDateInstant-
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)本社事務所 埼玉県川口市領家4丁目6番42号
Telephone number nearest place of contact cover pageFilingDateInstant048(222)5171
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)取締役経理部長  本 間 義 隆
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE01006
Fund codeFilingDateInstant-
Security codeFilingDateInstant43610
Filer name in japaneseFilingDateInstant
Original text (Japanese)川口化学工業株式会社
Filer name in englishFilingDateInstantKawaguchi Chemical Industry Co., Ltd
Fund name in japaneseFilingDateInstant-
Fund name in englishFilingDateInstant-
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第三号様式
Accounting standardsFilingDateInstantJapan GAAP
Whether consolidated financial statements are preparedFilingDateInstanttrue
Industry code when consolidated financial statements are prepared in accordance with industry specific regulationsFilingDateInstantcte

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 24 of 24 passed
balance sheet identityconsolidated 2022-11-30pass
balance sheet identityconsolidated 2023-11-30pass
balance sheet identitynon_consolidated 2022-11-30pass rounding
balance sheet identitynon_consolidated 2023-11-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2021-11-30pass
statement vs summary · net assetsconsolidated 2022-11-30pass
statement vs summary · net assetsconsolidated 2023-11-30pass
statement vs summary · net assetsnon_consolidated 2021-11-30pass
statement vs summary · net assetsnon_consolidated 2022-11-30pass
statement vs summary · net assetsnon_consolidated 2023-11-30pass
statement vs summary · net income attributable to parentconsolidated 2021-12-01/2022-11-30pass
statement vs summary · net income attributable to parentconsolidated 2022-12-01/2023-11-30pass
statement vs summary · operating cash flowconsolidated 2021-12-01/2022-11-30pass
statement vs summary · operating cash flowconsolidated 2022-12-01/2023-11-30pass
statement vs summary · revenueconsolidated 2021-12-01/2022-11-30pass
statement vs summary · revenueconsolidated 2022-12-01/2023-11-30pass
statement vs summary · revenuenon_consolidated 2021-12-01/2022-11-30pass
statement vs summary · revenuenon_consolidated 2022-12-01/2023-11-30pass
statement vs summary · total assetsconsolidated 2022-11-30pass
statement vs summary · total assetsconsolidated 2023-11-30pass
statement vs summary · total assetsnon_consolidated 2022-11-30pass
statement vs summary · total assetsnon_consolidated 2023-11-30pass